Full Year
PTN — FY2026 Annual Financial Report Analysis
Palatin's FY2026 net loss halved to $8.4M on $13.2M of one-time licensing income from Boehringer Ingelheim and Altanispac, but with $7.5M of cash the company flags going-concern doubt ahead of 2027 obesity-drug trials.